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Abstract Metformin is an oral antihyperglycemic agent used
in the management of type 2 diabetes mellitus. Lactic acidosis
from metformin overdose is a rare complication of metformin
therapy and occurs infrequently with therapeutic use. Fatal
cases, both accidental and intentional, are extremely rare in
clinical practice. Metformin is eliminated by the kidneys, and
impaired renal function can result in an increased plasma
concentration of the drug. In this report, we describe an
autopsy case involving a 70-year-old woman suffering from
diabetes mellitus and impaired renal function who received
metformin treatment. Metformin concentrations in the
peripheral blood collected during hospitalization and femoral
blood collected during autopsy were 42 and 47.3 µg/ml,
respectively. Lactic acidosis (29.10 mmol/l) was objectified
during hospitalization. Furthermore, postmortem biochemistry
allowed ketoacidosis to be diagnosed (bloodβ-hydroxybutyrate,
10,500 µmol/l). Death was attributed to lactic acidosis due to
metformin intoxication. Increased plasma concentrations of the
drug were attributed to severely impaired renal function. The
case emphasizes the usefulness of performing exhaustive
toxicology and postmortem biochemistry towards the more
complete understanding of the pathophysiological mechanisms
that may be involved in the death process.
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Introduction
Metformin is an oral antihyperglycemic agent used in the
management of type 2 diabetes mellitus. The mechanisms of
action are multifaceted and include decreased hepatic glucose
production (primarily through the inhibition of gluconeogenesis,
but also through glycogenolysis), increased insulin-stimulated
glucose uptake in skeletal muscle and adipocytes, as well as a
delayed glucose absorption rate from the gastrointestinal tract.
An additional pharmacologic effect is increased intestinal lactate
production. Metformin can be responsible for potentially life-
threatening metabolic acidosis with an increased blood lactate
level. Although rare, this condition carries a high risk ofmortality
and may occur in therapeutic use as well as in acute overdose.
Notwithstanding the complex pathogenesis, still not completely
understood, metformin-induced lactic acidosis is postulated as
being caused by enhanced lactate production in the intestines and
gluconeogenesis inhibition in the liver. Both of these
mechanisms would cause increased gluconeogenic substrate
concentration such as pyruvate and alanine. This would thus be
the key link between metformin and lactic acidosis [1–3].
Metformin overdose, both accidental and intentional, has
been commonly reported, though fatal cases are infrequent. In
the 2008 annual report of the American Association of Poison
Control Centers (AAPCC), 6,538 cases of biguanide exposure
were reported with 17 patients experiencing major adverse
outcomes and 8 deaths. A 5-year review of toxic exposures
reported in poison control centers in the USA revealed that
only 4,072 out of the nearly 11 million exposures involved
metformin, with a total of 9 deaths (0.2 % of all metformin-
related exposures), 32 cases with life-threatening signs or
symptoms and/or residual disability (0.8 %), and 187 cases
with moderate clinical effects (4.6 %) [1–5].
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Even though lactic acidosis is a rare complication relative to
the very widespread use of the drug, its possible occurrence
still influences treatment strategies in type 2 diabetes mellitus,
particularly in patients with impaired renal function and in
those with severely compromised oxygenation and tissue
perfusion that may predispose to increased lactate production.
Liver dysfunction, past history of lactic acidosis (of any cause),
chronic respiratory failure, and alcohol abuse are classic
contraindications to metformin use. Congestive heart failure
has recently been removed from the list of diseases absolutely
contraindicated with metformin administration, although a
warning for concomitant use in this condition remains [6–8].
In this report, we describe an autopsy case involving a 70-
year-old woman suffering from diabetes mellitus, obesity, and
impaired renal function who received metformin treatment.
Toxicology revealed markedly increased blood metformin
concentration, and biochemical investigations showed
increased vitreous lactate and increased blood and vitreous
β-hydroxybutyrate. The cause of death as well as the
relationships pertaining to ante- and postmortem laboratory
results, precipitating causes, and metabolic disturbances that
likely led to or contributed to death are herein discussed.
Case history
An obese (weight 117 kg, height 165 cm) 70-year-old woman
suffering from hypertension, type 2 diabetes mellitus, and
polyarthritis was admitted to the hospital due to fall-related
injuries mainly consisting of right patella fracture. On
admission, physical examination revealed a good general state
and mild edema in the lower extremities, whereas laboratory
analyses showed hyperglycemia, increased glycated
hemoglobin level, impaired renal function, and anemia.
During hospitalization (10 days), the patient received
irbesartan, furosemide, insulin, heparin, and metformin
(500 mg at 8 a.m., 1,000 mg at 1 p.m., and 1,000 mg at 7
p.m.). The patient was subsequently transferred to a
rehabilitation clinic. Physical examination performed on
admission showed mild edema in the lower extremities as
well as a distended abdomen. Cardiac function and
hemodynamic status were relatively stable. The prescribed
treatment consisted of heparin anticoagulation once daily,
irbesartan 300 mg, furosemide 125 mg, insulin administered
three or more times per day by injection, and metformin
(500 mg at 8 a.m., 1,000 mg at 1 p.m., and 1,000 mg at 7
p.m.). Insulin treatment was stopped 2 days after admission
due to a lack of appetite and insufficient food intake. Three
days after admission, blood glucose level was 230 mg/ml
(12.8 mmol/l), and 5 units of insulin was administered. Four
days after admission, the patient complained of severe itching
and orticarioid-like reaction of the abdomen. An
antihistaminic agent (cetirizine) was then added to the daily
treatment. Five days after admission, neither insulin nor
metformin was administered due to a worsening lack of
appetite and insufficient food intake. Six days after admission,
the patient had an episode of biliary vomit associated with
chest, epigastric, and abdominal pain. Metformin was
administered again at full dose (2,500 mg). Physical
examination revealed icteric sclera. The patient became
agitated and was transferred to the intensive care unit of the
local hospital. On admission, the patient lost consciousness,
and cardiorespiratory arrest occurred. Cardiopulmonary
resuscitation allowed only a partial hemodynamic recovery.
Laboratory investigations showed lactic metabolic acidosis,
hyperkalemia, and impaired renal function. Four hours
postadmission, laboratory analyses showed no improvement.
The patient died 8 h after admission despite resuscitation
attempts. A medicolegal autopsy was ordered by the local-
inquiring authorities (public prosecutor) due to the unclear
circumstances of death as well as possible correlations
between medical malpractice and the fatal outcome.
External examination, autopsy, and histology
Height was 165 cm andweight 117 kg (BMI 40 kg/m2). External
examination revealed the presence of abdominal bruises and
linear excoriations on the skin of different body parts, particularly
the abdomen and left thigh. Edema of the facewas also observed.
Internal examination revealed rib fractures and intercostal space
hemorrhagic infiltrations consistent with cardiopulmonary
resuscitation marks. The heart weighted 450 g. Heart
examination revealed mild left ventricle hypertrophy.
Examination of the pleural cavities showed bilateral effusion
(approximately 100 ml in each cavity). The lungs were relatively
edematous and congested (right lung 650 g, left lung 550 g). On
cut section, both edematous lungs showed subpleural
emphysematous areas in both apexes with no evidence of any
focal lesions. Pulmonary embolismwas not observed. The spleen
weighed 200 g and was moderately enlarged with a tense,
smooth capsule and congested parenchyma. The cut section of
the liver that weighed 2,100 g was congested and showed
multiple yellow areas. No identifiable pill components or
fragments were found in the stomach contents or upper
gastrointestinal tract. The brain and the kidney were
macroscopically unremarkable.
Histology confirmed the presence of left ventricular
hypertrophy with no evidence of subendocardial hemorrhage
or acute myocardial infarction. The lungs showed congestion
and edema as well as areas of emphysema, atelectasis, and
hemorrhage foci. Immunohistochemistry of the lungs using
antitryptase antibodies was negative. Histology also revealed
congestion and areas of fatty degeneration of the liver as well
as diffuse mesangial sclerosis and nodular glomerulosclerosis
(Kimmelstiel–Wilson lesion) of the kidneys.
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Toxicology and biochemistry
Peripheral blood from the femoral vein, cardiac blood, bile
and vitreous humor, as well as samples of certain tissues were
recovered for toxicological and biochemical analyses.
Toxicology included ethanol and other volatile compounds
determination as well as general screening for nonvolatile
drugs, poisons, and metabolites by gas chromatography–mass
spectrometry (GC-MS) using commercial mass spectrum
libraries, high-performance liquid chromatography with diode
array detection (HPLC-DAD), and headspace–gas
chromatography–flame ionization detection (HS-GC-FID) for
volatile compound analysis.
Metformin analysis was performed utilizing a reverse-phase
(RP) HPLC method. Phenformin (another biguanide derivative)
was chosen as internal standard. The two compounds were
separated in a C18 column by a mixture of acetonitrile–
methanol–water (45:10:45%) containing sodium dodecyl sulfate
(NaDS) 0.01 M. The mobile phase was adjusted to pH 4.0 with
acetic acid. Diode array detector was employed for the
quantitative analysis of the analytes. The metformin
concentration in the blood was measured at 230 nm. The blood
sample was simply deproteinized by acetonitrile, diluted 1:5 with
hydrochloric acid 0.01 M, and directly injected in the HPLC
system. A five-point calibration curve was studied within the
range of 5–100 mg/l.
Acetone was determined during ethanol analysis in the
blood by usingHS-GC-FID. Toxicology failed to detect ethanol
and revealed the presence of lidocaine (within therapeutic
range), acetone (120 mg/l, corresponding to 12 mg/dl and 2,
070 μmol/l), and metformin (47.3 μg/ml) in the femoral blood
collected during autopsy (therapeutic range 0.5–2.5 μg/ml).
Metformin concentration in the peripheral blood collected
during hospitalization and prior to death was 42 μg/ml.
Biochemical investigations were performed in the femoral
blood and vitreous humor. Glycated hemoglobin was
determined in the whole femoral blood. Glucose, sodium,
chloride, and lactate were measured in vitreous. Beta-
hydroxybutyrate was determined in the blood and vitreous.
Vitreous sodium, chloride, glucose, and lactate were
determined by enzymatic assays on a Dimension® Xpand®
Plus Integrated Chemistry System (Siemens Healthcare
Diagnostics, Inc., Deerfield, IL, USA). The concentrations
of all substances were determined without diluting samples.
Glycated hemoglobin was determined on the whole femoral
blood stored in tubes containing ethylenediaminetetraacetic
acid (EDTA) by ion-exchange HPLC (Bio-Rad D-10 Dual
Program, Hercules, CA, USA).
Beta-hydroxybutyrate concentrations were determined on
Cobas Mira Plus (Roche Diagnostics, Switzerland) by an
enzymatic photometric method adapted in house from the
technique described by Ruell and Gass. Frozen femoral blood
and vitreous humor samples were thawed overnight at 4 °C
and deproteinized with perchloric acid. Supernatant was
used for analysis.
Results of analyzed biological fluids and clinical reference
values are summarized in Table 1. Based on the results of
clinical data and postmortem investigations, the cause of death
was determined to be terminal cardiocirculatory arrest
resulting from lactic acidosis due to metformin intoxication.
Discussion
Lactic acidosis is the most frequent cause of metabolic
acidosis and can result from an imbalance of lactic acid
production and degradation. Cases of lactic acidosis are
conventionally classified into type A (anaerobic) and type B
(aerobic). Type A occurs in situations characterized by tissue
hypoperfusion and hypoxia, whereas type B includes all other
forms with no evidence of tissue hypoxia. It must be
highlighted, however, that this distinction has become partly
obsolete, since restricted oxygen supply and metabolic factors
often act simultaneously [6, 9].
A serious adverse effect of metformin in certain individuals
is type B lactic acidosis, also known as metformin-associated
lactic acidosis (MALA). Metformin is a small molecule
(molecular weight, 165.8 Da) that is primarily absorbed from
the small intestine. Metformin absorption is incomplete, with
20–30 % found in the feces. Oral bioavailability is 40–60 %,
depending on the dose ingested, with greater doses producing
lower bioavailability. Metformin is thought to have a plasma t
of 0.5 between 4 and 8.7 h, minimal protein binding. The drug
is mainly excreted unchanged by the kidney (90 %) with a
clearance 3.7 to 5 times the creatinine clearance. The rate of
absorption is slower than the rate of elimination, which makes
absorption to be a late-limiting step in the elimination half-life
[10, 11].
The pathophysiology of MALA is not completely
understood and is thought to be due to a shift in the intracellular
redox potential from aerobic to anaerobic metabolism and
decreased lactate utilization by suppression of hepatic
gluconeogenesis. The occurrence of MALA has been generally
observed during therapeutic dosage rather than overdose. In
patients with normal renal function, about 90% of the absorbed
metformin is eliminated and unchanged by glomerular filtration
and tubular secretion within the first 24 h. Traditional theory
suggests that MALA occurs in the context of comorbidities that
may result in drug accumulation (such as impaired renal
function), elevated circulating lactate levels, or both. The link
between metformin administration and lactic acidosis has been
called into question by some, suggesting that MALA has
typically been observed in the setting of other illnesses that
are more likely to be the cause of lactic acidosis rather than
incriminating metformin itself. Some data showed that
metformin accumulation in the blood does not necessarily lead
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to lactic acidosis and failed to confirm the existence of a
correlation between blood metformin levels and mortality,
suggesting that the underlying causes of acidosis play a more
important role thanmetformin administration itself on outcome.
However, lactic acidosis during metformin treatment has been
observed in patients with normal kidney function and without
underlying conditions predisposing them to renal failure,
hypoxia, and lactic acid accumulation [10–14].
There are only few data regarding MALA in the setting of
acute metformin overdose, though several cases of severe lactic
acidosis following acute metformin ingestion have been
clinically documented. The annual report of the AAPCC
regularly mentions fatal cases in which acute metformin
ingestion is most probably or undoubtedly responsible for death.
Though some authors have denied any causal involvement and
postulated that lactic acidosis in acute overdose is primarily due
to the hemodynamic instability and shock syndrome following
drug ingestion rather than the metabolic effects of metformin
itself, the conclusions of other studies have suggested that severe
lactic acidosis may also occur after acute metformin mono-
overdose in the absence of comorbidities. Clinical data and
retrospective observation are at present not suitable to decide
upon this issue definitively [12–16].
Since MALA occurs infrequently with therapeutic use and
fatal cases are extremely rare in clinical practice, only a few
reports exist in the literature with both complete antemortem
medical records and detailed postmortem investigation
findings. In most cases, exhaustive clinical and postmortem
analysis results are absent or partially available. In Table 2, we
have summarized the main clinical and postmortem findings
(where available) in fatal cases related to therapeutic use or
suicidal ingestion that we have collected upon literature
review and the annual reports of the AAPCC from 2009 to
2011. Other fatal cases following therapeutic administration
or suicidal use are mentioned in case series reports, but
with limited available clinical and postmortem information
[3, 9, 14, 17–31].
Lactic acidosis from metformin overdose is clinically
indistinguishable from other forms of lactic acidosis. However,
since MALA is primarily caused by impaired lactate clearance
by the liver and is not the direct result of tissue hypoxia, the
degree of clinical severity in these patients is generally not as
important as in patients with lactic acidosis from other causes.
Symptoms are often unspecific. Severe acidosis often leads to
significant vasodilatation (due to decreased catecholamine
binding to their respective receptors) and depressed myocardial
contractility. Both of these mechanisms are thought to
contribute to hypotension and hypoperfusion in severely
acidemic patients, in turn leading to oliguria, acute renal
insufficiency, and multisystem organ failure [3, 10, 18, 32].
The label on metformin in the USA is explicit with respect
to renal contraindications and suggests drug administration
based on serum creatinine cut points. Clinical guidelines
outside of the USA incorporate the glomerular filtration rate
(GFR) for the determination of metformin safety. Despite the
clear recognition that impaired renal function may be a risk
factor for adverse events with metformin use, a significant
divergence regarding optimal conditions of safety exists
across the globe [33–36].
In the case herein described, the cause of death was
determined to be terminal cardiocirculatory arrest resulting from
lactic acidosis due to metformin intoxication. Lactic acidosis was
diagnosed through clinical laboratory analyses (blood lactate
15 mmol/l and pH 6.80 on admission to the intensive care unit
and blood lactate 29.10 mmol/l 4 h postadmission). The role of
metformin as the main contributing factor in the development of
lactic acidosis was easily identified based on the high drug
concentrations in both blood sample collected during
hospitalization (42 μg/ml) and femoral blood obtained during
autopsy (47.3 μg/ml). Metformin accumulation was caused by
severely impaired renal function, thus confirming that
prescription was absolutely contraindicated in this patient.
Accordingly, the forensic investigations led to the accused
clinicians (those of the hospital as well as those of the
rehabilitation clinic) being considered guilty of manslaughter
by the public prosecutor.
Based on the available data, metformin appears to be
minimally susceptible to postmortem redistribution [17].
Blood levels ranging from 0.5 to 2.5 μg/ml are considered
within the therapeutic range, whereas concentrations over
5 μg/ml are generally considered toxic [17–31]. Lethal
concentrations cannot be precisely defined. Cantrell et al.
[17] described the case of a 57-year-old-woman with an
antemortem blood metformin concentration of 210 mg/l and
emphasized that the highest reported antemortem metformin
concentration in which the patient survived was 165 mg/l,
though other authors described antemortem metformin
concentrations of up to 380 mg/l. Dell’Aglio et al. [3]
analyzed 22 cases of acute metformin overdose and observed
that the mortality rate in patients with a peak serummetformin
concentration of greater than 50 μg/ml was 38 %, with a
median peak metformin level of 110 μg/ml in nonsurvivors.
In the presented case, vitreous glucose value lower than
0.1 mmol/l indicated the absence of hyperglycemia when
the patient died. Interestingly, markedly increased
β-hydroxybutyrate levels were found in the blood
(10,500 μmol/l) and vitreous (9,500 μmol/l). Fasting was
postulated as the cause of this ketoacidosis, which was
plausible retrospectively in a patient who had insufficient
food intake and prolonged emesis the days prior to death.
Since ante- and postmortem laboratory investigations
excluded concomitant hyperglycemia, alternative causes
for this patient’s hyperketonemia seemed unlikely. What is
remarkable in the case herein described is that concomitant
metformin accumulation prevented gluconeogenesis, thus
aggravating ketogenesis and ketoacidosis caused by fasting.
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Lastly, it must be emphasized that severe lactic acidosis
could be reliably identified only through antemortem
biochemical investigations and that the increased vitreous
lactate concentration revealed by postmortem biochemistry
(270 mg/dl, corresponding to 30 mmol/l) would have not
allowed antemortem lactic acidosis to be correctly diagnosed.
Indeed, postmortem vitreous lactate levels of 30 mmol/l–
270 mg/dl cannot be considered as a diagnostic evidence of
antemortem lactic acidosis since values within this range are
commonly found in vitreous after death. It has been shown that
vitreous lactate levels rise with increasing postmortem time and
that the postmortem vitreous lactate concentrations are due not
only to the antemortem vitreous lactate levels and the
postmortem metabolism of glucose, but other sources can also
be responsible for lactate formation in vitreous and subsequent
increased vitreous lactate concentrations after death. These
observations confirm that the postmortem identification of
lactic acidosis as the cause of death is a very difficult diagnosis
in the absence of a suggestive context and that the correlation of
medical history, autopsy observations, histology findings, and
postmortem biochemical results is often decisive in identifying
the cause of death, the precipitating conditions, and the
predisposing disorders [37–39].
To conclude, though metformin is a highly effective, well-
tolerated, and generally safe antihyperglycemic agent in the
treatment of type 2 diabetes, a significant risk of toxicity has
been associated with its use in certain types of patients. The
fatal case herein described is compatible with previous reports
of metformin overdose and death in patients presenting risk
factors that contributed to drug accumulation in blood and lactic
acid generation. Since the potential toxicity of the drug is
multifold, the determination of comorbidities and coingestants
that may synergistically contribute to the toxic effects of
metformin is of paramount importance in order to properly
identify patients at particular risk for increased blood lactate
levels.
Lastly, the presented case emphasizes the usefulness of
performing exhaustive toxicology and postmortem
biochemical analyses and correlating all potentially relevant
investigations toward the more complete understanding of the
pathophysiological mechanisms that may be involved in the
death process.
Acknowledgments Authors are grateful to the anonymous reviewers,
whose constructive and useful comments improved the quality of the
article.
References
1. Al-Abri SA, Hayashi S, Thoren KL, Olson KR (2013) Metformin
overdose-induced hypoglycemia in the absence of other antidiabetic
drugs. Clin Toxicol (Phila) 51(5):444–447
2. Moore KA, Levine B, Titus JM, Fowler DR (2003) Analysis of
metformin in antemortem serum and postmortem specimens by a
novel HPLC method and application to an intoxication case. J Anal
Toxicol 27(8):592–594
3. Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD,
Morgan BW (2009) Acute metformin overdose: examining serum
pH, lactate level, and metformin concentrations in survivors versus
nonsurvivors: a systematic review of the literature. Ann Emerg Med
54(6):818–823
4. Suchard JR, Grotsky TA (2008) Fatal metformin overdose presenting
with progressive hyperglycemia. West J Emerg Med 9(3):160–164
5. Mizzi A, Landoni G, Corno L, Fichera M, Nuzzi M, Zangrillo A
(2009) How to explain a PaO2 of 140 mmHg in a venous line? Acta
Biomed 80(3):262–264
6. Lalau JD (2010) Lactic acidosis induced by metformin: incidence,
management and prevention. Drug Saf 33(9):727–740
7. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA
(2008) Levels of evidence needed for changing indications,
contraindications, and Food and Drug Administration labeling: the
case of metformin. Arch Intern Med 171(11):1042–1043
8. Nye HJ, Herrington WG (2011) Metformin: the safest
hypoglycaemic agent in chronic kidney disease? Nephron Clin
Pract 118(4):c380–c383
9. Krzymień J, Karnafel W (2013) Lactic acidosis in patients with
diabetes. Pol Arch Med Wewn 123(3):91–97
10. Spiller HA, Sawyer TS (2006) Toxicology of oral antidiabetic
medications. Am J Health Syst Pharm 63(10):929–938
11. Mujtaba M, Geara AS, Madhrira M, Agarwala R, Anderson H,
Cheng JT, Mohan S (2012) Toxicokinetics of metformin-associated
lactic acidosis with continuous renal replacement therapy. Eur J Grud
Metab Pharmacokinet 37(4):249–253
12. Wills BK, Bryant SM, Buckley P, Seo B (2010) Can acute overdose of
metformin lead to lactic acidosis? Am J Emerg Med 28(8):857–861
13. Spiller HA, Quadrani DA (2004) Toxic effects from metformin
exposure. Ann Pharmacother 38(5):776–780
14. Lalau JD, Mourlhon C, Bergeret A, Lacroix C (1998) Consequences
of metformin intoxication. Diabetes Care 21(11):2036–2037
15. Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR,
Williams KM, Day RO (2013) The role of metformin in metformin-
associated lactic acidosis (MALA): case series and formulation of a
model of pathogenesis. Drug Saf. doi:10.1007/s40264-013-0038-6
16. Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M
(2005) Severe metformin intoxication with lactic acidosis in an
adolescent. Eur J Pediatr 164(6):362–365
17. Cantrell LF, Nelson CL, Gary RD, McIntyre IM (2012) Fatal
metformin intoxication with markedly elevated blood and liver
concentrations. J Anal Toxicol 36(9):657–659
18. Gambaro V, Dell’acqua L, Farè F, Fidani M, Froldi R, Saligari E
(2007) A case of fatal intoxication from metformin. J Forensic Sci
52(4):988–991
19. Nisse P, Mathieu-Nolf M, Deveaux M, Forceville X, Combes A
(2003) A fatal case of metformin poisoning. J Toxicol Clin Toxicol
41(7):1035–1036
20. Hermann LS, Magnusson S, Möller B, Casey C, Tucker GT, Woods
HF (1981) Lactic acidosis during metformin treatment in an elderly
diabetic patient with impaired renal function. Acta Med Scand
209(6):519–520
21. Sánchez-Rubio Ferrández L, Martínez Iturriaga S, Hurtado Gómez
MF, Apiñaniz Apiñaniz R (2013) Suicide to massive ingestion of
metformin (85 g): lactic acidosis followed by rhabdomyolysis with
fatal heart damage. Farm Hosp 37(2):166–167
22. Orban JC, Giunti C, Levraut J, Grimaud D, Ichai C (2003)
Metformin-associated lactic acidosis remains a serious complication
of metformin therapy. Ann Fr Anesth Reanim 22(5):461–465
23. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC
(2012) 2011 annual report of the American Association of Poison
Int J Legal Med (2014) 128:483–492 491
Control Centers’ National Poison Data System (NPDS): 29th annual
report. Clin Toxicol (Phila) 50(10):911–1164
24. Perrone J, PhillipsC,GaieskiD (2011)Occultmetformin toxicity in three
patients with profound lactic acidosis. J Emerg Med 40(3):271–275
25. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH,
Dart RC (2011) 2010 annual report of the American Association of
Poison Control Centers’ National Poison Data System (NPDS): 28th
annual report. Clin Toxicol (Phila) 49(10):910–941
26. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH,
Giffin SL (2010) 2009 annual report of the American Association of
Poison Control Centers’ National Poison Data System (NPDS): 27th
annual report. Clin Toxicol (Phila) 48(10):979–1178
27. Arroyo AM,Walroth TA,Mowry JB, Kao LW (2010) The MALAdy
ofmetformin poisoning: is CVVH the cure? Am J Ther 17(1):96–100
28. Barrueto F,MeggsWJ, BarchmanMJ (2002) Clearance of metformin
by hemofiltration in overdose. J Toxicol Clin Toxicol 40(2):177–180
29. Bismuth C, Gaultier M, Conso F, Assan R, Heuclin C (1976) Lactic
acidosis induced by excessive ingestion of metformin. Eur J Toxicol
Environ Hyg 9(1):55–57
30. Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR
(1977) Metformin-induced lactic acidosis in the presence of acute
renal failure. Diabetologia 13(3):211–217
31. Ortega Carnicer J, Ambrós Checa A, Martín Rodríguez C, Ruiz
Lorenzo F, Portilla Botelho M, Gómez Grande L (2007) Overdose
of metformin secondary to acute renal insufficiency: a report of six
cases. Med Intensiva 31(9):521–525
32. Dell’Aglio DM, Perino LJ, Todino JD, Algren DA, Morgan BW
(2010) Metformin overdose with a resultant serum pH of 6.59:
survival without sequelae. J Emerg Med 39(1):e77–e80
33. Kosmalski M, Drozdowska A, Sliwinska A, Drzewoski J
(2012) Inappropriate metformin prescribing in elderly type 2
diabetes mellitus (T2DM) patients. Adv Med Sci 57(1):65–
70
34. Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P,
Schumm-Draeger PM (2013) The role of co-morbidity in the
selection of antidiabetic pharmacotherapy in type-2 diabetes.
Cardiovasc Diabetol 12:62
35. LipskaKJ, BaileyCJ, Inzucchi SE (2011)Use ofmetformin in the setting
of mild-to-moderate renal insufficiency. Diabetes Care 34(6):1431–1437
36. Devetzis V, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E,
Georgoulidou A, Vargemezis V (2011) Metformin-related lactic
acidosis in patients with acute kidney injury. Int Urol Nephrol
43(4):1243–1248
37. Boulagnon C, Garnotel R, Fornes P, Gillery P (2011) Postmortem
biochemistry of vitreous humor and glucose metabolism: an update.
Clin Chem Lab Med 49(8):1265–1270
38. Zilg B, Alkass K, Berg S, Druid H (2009) Postmortem identification
of hyperglycemia. Forensic Sci Int 185(1–3):89–95
39. Palmiere C, Sporkert F, Vaucher P, Werner D, Bardy D, Rey F, Lardi
C, Brunel C, AugsburgerM,Mangin P (2012) Is the formula of Traub
still up to date in antemortem blood glucose level estimation? Int J
Legal Med 126(3):407–413
492 Int J Legal Med (2014) 128:483–492
